Cept, plus the IL12/23 antagonist ustekinumab. Initial, the information show weak-to-moderate
Cept, as well as the IL12/23 antagonist ustekinumab. Initially, the information show weak-to-moderate, however significant, correlations amongst biomarkers of systemic inflammation and PASI below biologic therapy. NLR and CRP, in…